L'intérêt à découvert pour Septerna donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Septerna. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Septerna (NASDAQ:SEPN) Stock, Rapport sur les intérêts à découvert

SEPTERNA INC

Septerna

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

Septerna Inc

Harte-Hanks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HHS#NASDAQ">HHS</a>) reported quarterly losses of $(0.05) per share. This is a 150 percent decrease over losses of $(0.02) per share from the same period last year. The company reported $41.56 million in sales this quarter. This is a 8.55 percent decrease over sales of $45.45 million the same period last year.

Earnings

News

UPDATE: Harte-Hanks Q1 EPS $(0.05) Down From $(0.02) YoY, Sales $41.56M Down From $45.45M YoY

S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) has outperformed the market over the past 10 years by 6.22% on an annualized basis producing an average annual return of 16.9%. Currently, S&amp;P Global has a market capitalization of $157.00 billion. 
Buying $1000 In SPGI: If an investor had bought $1000 of SPGI stock 10 years ago, it would be worth $4,774.67 today based on a price of $511.94 for SPGI at the time of writing.
<h3>S&amp;P Global's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747265415_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

SPGI

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

Arch Capital Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>) has outperformed the market over the past 20 years by 7.5% on an annualized basis producing an average annual return of 15.77%. Currently, Arch Capital Group has a market capitalization of $34.05 billion. 
Buying $1000 In ACGL: If an investor had bought $1000 of ACGL stock 20 years ago, it would be worth $18,646.52 today based on a price of $90.85 for ACGL at the time of writing.
<h3>Arch Capital Group's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747264516_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACGL

Here's How Much You Would Have Made Owning Arch Capital Group Stock In The Last 20 Years

A lot of people fantasize about what they'd do if they had billionaire money—hire a chef, get a driver, finally stop buying store-brand cereal. Mark Cuban? He's over here clipping virtual coupons and doing his own laundry.
With an <a href="https://www.benzinga.com/personal-finance/25/02/43885487/billionaire-mark-cuban-said-the-first-step-to-getting-rich-is-giving-things-up-drink-water-eat-mac-and-cheese-and-save-every-penny">estimated net worth around $6 billion</a>, you'd think you'd think the entrepreneur might be too busy sailing around on a yacht or bossing around a butler to care about Amazon discounts. But in true Cuban fashion, he says no thanks to all of it—and not for the cameras, but because he genuinely doesn't see the point.
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
"I just try to be the same person as I was when I was poor and middle and rich," Cuban told TikTok creator Bobbi Althoff on <a href="https://youtu.be/keN-qiRfU3c?si=fFcKXlGqZuD3OI4-">"The Really Good Podcast"</a> in 2023. "When I was broke, I had a blast. I loved my life. I could wake up smiling, and back then, you just had to not answer the phone because it'd be a bill collector."
Althoff—known for her dry humor and uncomfortable interview setups—met Cuban in a parking garage, where he sat on the floor and casually revealed he doesn't have a butler. "People think you gotta make new friends or you got butlers," he said. When asked directly, he confirmed: "No."
She pushed further—does he do his own laundry? "I'm capable, yeah," Cuban replied. "It takes two seconds. It's just easier."
Trending: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
And Cuban isn't just skimping on hired help. Back in 2017, in an <a href="https://www.vanityfair.com/video/watch/mark-cuban-s-guide-to-getting-rich">interview with Vanity Fair</a>, he explained that he literally buys toothpaste in bulk to save money. "It's so hard to make a return on regular investments that… you're better off buying two years' worth of toothpaste when it's on 50% discount," he said. He sees it as an "immediate return on your money."
And it doesn't stop at dental hygiene. "Any <a href="https://www.benzinga.com/personal-finance/25/03/44065932/mark-cuban-was-asked-how-hed-invest-100k-his-answer-buy-bulk-toothpaste-and-soup-for-the-best-guaranteed-return-on-investment">reusables or consumables</a> that you have to have—when they're on a huge sale on Amazon, buy them," he said. "Because chances are, their prices are going to go up. That's a real savings that you get to put in your pocket."
Even with billionaire status, Cuban still checks his budget every year, looking for ways to trim costs. He's also <a href="https://www.benzinga.com/personal-finance/24/05/39092288/if-you-use-your-credit-card-you-do-not-want-to-be-rich-warns-mark-cuban-on-the-dave-ramsey-show">famously against credit card debt</a>, advises people to save six months' worth of expenses, and encourages old-school, face-to-face negotiation. "If you're going to take a yoga class and they want to charge you $30, say, ‘I got $20,'" he told Vanity Fair. "They're gonna take it. Negotiating with cash is a far better way to get a return on your investment."
See Also: The team behind $6B+ in licensing deals is now building the next billion-dollar IP empire — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">invest early at $2.25/share.</a>
As for hanging out with other billionaires? He knows a few. But most of his friends, he told Althoff, are the same ones he's had since Pittsburgh, Indiana, or early Dallas days. The people who knew him long before the billions.
Cuban's not against wealth—he just doesn't need to flaunt it. "The whole idea of like, get a yacht… it's just not what I would do," he said.
There's a reason Mark Cuban still comes across like a guy you could run into at Costco—and maybe ask for toothpaste tips while you're at it.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

Billionaire Mark Cuban Doesn't Spend Money On A Housekeeper And Buys Toothpaste In Bulk  —'I Just Try To Be The Same Person I Was When I Was Poor'

Ameriprise Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) has outperformed the market over the past 15 years by 6.99% on an annualized basis producing an average annual return of 18.97%. Currently, Ameriprise Finl has a market capitalization of $49.82 billion. 
Buying $100 In AMP: If an investor had bought $100 of AMP stock 15 years ago, it would be worth $1,264.96 today based on a price of $521.67 for AMP at the time of writing.
<h3>Ameriprise Finl's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747263632_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Ameriprise Finl 15 Years Ago Would Be Worth Today

UnitedHealth Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has fallen nearly 50% over the past month, fueled by a series of <a href="https://www.benzinga.com/25/05/45388424/stock-of-the-day-where-will-the-unitedhealth-meltdown-end">negative catalysts. </a>
Several analysts have slashed price targets on the stock, but one analyst has seen enough and downgraded UnitedHealth on Wednesday.&nbsp;
What To Know: BofA Securities analyst Kevin Fischbeck downgraded UnitedHealth Group from Buy to Neutral and slashed the price target from $560 to $350 after the company pulled its 2025 outlook and announced a CEO transition on Tuesday. 
Read Next: <a href="https://www.benzinga.com/general/health-care/25/05/45384935/trump-again-promises-lower-drug-prices-by-cutting-out-middlemen-like-unitedhealth-cvs-will-it-work-this-time?utm_source=articleShare">Trump Again Promises Lower Drug Prices By &#8216;Cutting Out Middlemen&#8217; Like UnitedHealth, CVS: Will It Work This Time?</a>
UnitedHealth pulled<a href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance"> its guidance</a> after the company noticed its Medicare Advantage trend worsening and spreading to more complex patients, like dual enrollments. The analyst said the worsening trend became clear after UnitedHealth completed its March claims and had an early look at April's claims. 
Fischbeck views the health care giant&#8217;s decision to pull its fiscal guidance as a combination of uncertainty around the prevalence of higher utilization rates and to allow time for the incoming CEO to adjust.&nbsp;
Andrew Witty unexpectedly <a href="https://www.benzinga.com/pressreleases/25/05/b45370370/unitedhealth-group-announces-leadership-transition">resigned </a>as CEO "due to personal reasons" on Tuesday and will be succeeded by Stephen J. Hemsley, who served as UnitedHealth's CEO from 2006 to 2017. 
What Else: UnitedHealth shareholders<a href="https://www.benzinga.com/general/health-care/25/05/45305392/unitedhealth-investors-claim-company-hid-profit-impact-of-ceos-murder"> filed a lawsuit</a> last week that alleges the company misled investors by concealing the negative business impacts that followed the December 2024 killing of UnitedHealthcare <a href="https://www.benzinga.com/news/legal/25/02/43887520/luigi-mangione-back-in-court-friday-supporters-donate-500k-to-suspected-killer">CEO Brian Thompson.</a>
The company is still reeling from a major cyberattack on its Change Healthcare subsidiary and also faces intense regulatory and legal scrutiny, including federal investigations into its Medicare billing practices.
The recent convergence of disappointing earnings, surging medical costs, pulled forward guidance, abrupt leadership change and regulatory challenges have undermined investor confidence and triggered a dramatic revaluation of UnitedHealth stock over the past month.&nbsp;
UNH Stock Price Action: UnitedHealth Group shares ended Wednesday's session down 1.08% at $308.01, according to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>. 
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/health-care/25/05/45305392/unitedhealth-investors-claim-company-hid-profit-impact-of-ceos-murder">UnitedHealth Investors Claim Company Hid Profit Impact Of CEO&#8217;s Murder</a></li>
</ul>
Photo: Shutterstock

Downgrades

Health Care

Analyst Ratings

Movers

Insurance

General

UnitedHealth Stock Caught In A Perfect Storm, Falls Nearly 50% Since April

Linde (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NASDAQ">LIN</a>) has outperformed the market over the past 5 years by 3.56% on an annualized basis producing an average annual return of 18.58%. Currently, Linde has a market capitalization of $210.90 billion. 
Buying $100 In LIN: If an investor had bought $100 of LIN stock 5 years ago, it would be worth $231.97 today based on a price of $445.97 for LIN at the time of writing.
<h3>Linde's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747262716_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Linde 5 Years Ago Would Be Worth This Much Today

When you find your dream home—whether it's the wraparound porch, the walk-in pantry, or just the feeling that it's finally yours—logic can take a backseat. Especially when you're 28 and standing on the <a href="https://www.benzinga.com/personal-finance/24/10/41528892/can-you-guess-the-real-price-of-achieving-the-american-dream-heres-a-hint-youll-need-way-more-th">edge of the American Dream</a> with a pen in one hand and a contract in the other.
That's where Stephanie found herself. She <a href="https://youtu.be/z-iypKuypTU?si=a0MCNQScIaYIdzDZ">called in to "The Ramsey Show</a>" from Arlington, Virginia, hoping for a thumbs-up from the personal finance legend himself. What she got instead? A very loud, very blunt: "You're too broke."
Don't Miss:
<ul class="wp-block-list">
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
<li>Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a></li>
</ul>
Stephanie, who said she's been renting since graduating college, recently went under contract to buy a $760,000 home. Her plan? Use the sale of her employee stock to cover part of the down payment, then <a href="https://www.benzinga.com/personal-finance/24/09/41075540/is-your-401-k-balance-above-average-find-out-if-youre-beating-most-savers">pull the rest from her 401(k)</a>, cash out her Roth IRA, and absolutely not touch her crypto.
"I thought that would be an option to sell my crypto," she told Ramsey, "but it sounds like Freddie Mac and such have not made legislation that allows me to use that."
Ramsey wasn't buying it—literally or figuratively. "No," he said flatly. "If you sell your crypto and you have the cash, sell the crypto."
When she revealed she had about $30,000 worth of it, but wanted to keep it, Ramsey fired back: "You're broke. Sell it."
Trending: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
To be clear, Stephanie makes around $130,000 a year and had already put down earnest money. But her remaining cash was tied up in retirement accounts and crypto—none of which Ramsey considered liquid or smart to mess with for a house. Especially not one this expensive.
"You're going to get hit with a 10% penalty plus your tax rate," Ramsey warned. "You're going to get hit with 40%." Then, delivering one of the most memorable lines of the segment, he said, "Dave, I want to borrow money at 40% interest to buy this house… I would say no, don't do that. That doesn't sound wise. And that is exactly what you're doing."
Ramsey wasn't finished. He told her she needed at least $20,000 in the bank after closing or she'd be one bad roof away from financial disaster. "As soon as you move in, crap's gonna fall in," he said. "You're asking for trouble being broke and buying a house."
See Also: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
In the end, his advice was clear: sell the crypto, <a href="https://www.benzinga.com/personal-finance/25/05/45181755/58-year-old-with-no-retirement-says-his-ex-left-him-broke-and-hes-sick-of-working-dave-ramsey-says-he-can-build-a-500k-nest-egg-in-10-years">don't touch retirement accounts</a>, and make sure there's a cash cushion to fall back on. "It's not a blessing to buy a house when you're broke," he said. "You just got the 28-year-old fever. I gotta have a house. Especially a three-quarter-of-a-million-dollar house."
As for the crypto loyalty? Ramsey didn't hold back: "It's cool to sit at some hipster bar and be like, ‘I got crypto.' You're broke. Sell it."
It wasn't the pep talk Stephanie may have hoped for—but it was pure, unfiltered Dave Ramsey. And for anyone rushing headfirst into homeownership with big dreams and zero reserves, the message was simple: the bank may approve you, but that doesn't <a href="https://www.benzinga.com/money/are-you-rich">mean you can actually afford it</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Image: Shutterstock

28-Year-Old Refuses to Sell Crypto, But Wants to Drain Her 401(k) And IRA For A $750K House — Dave Ramsey Tells Her 'You're Too Broke'

Leading sports brand ESPN is launching a new direct-to-consumer streaming platform under the flagship ESPN brand. Here's a look at what this means for Walt Disney Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) and<a href="https://www.benzinga.com/topic/streaming"> the streaming sector.</a>
What Happened: ESPN announced this week that<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40946689/disney-faces-more-change-ahead-as-espn-dtc-launch-will-accelerate-cord-cutting-nba-"> its long-awaited DTC</a> streaming platform will debut in the fall with a $29.99 per month price point.
"We are providing everything ESPN has to offer directly to fans and all in one place," ESPN Chairman Jimmy Pitaro <a href="https://www.espn.com/espn/story/_/id/45126967/espn-direct-consumer-streaming-service-set-fall-launch">said</a>.
Pitaro said ESPN is the most "trusted, loved and recognized name in sports."
"Our straightforward approach to name and pricing will help fans cut through the clutter, and provide them compelling options to access all our content within the enhanced ESPN App."
Pitaro said the app will be "the ultimate sports destination."
ESPN announced that users can buy an annual subscription for $299 per year, saving on the monthly cost.
ESPN+, the company's already existing streaming platform, will continue to be offered for $11.99 per month or $119 per year. There is also bundling options with other Disney streaming platforms, including Disney+ and Hulu.
Consumers who subscribe to the new streaming app will get access to seven ESPN domestic linear networks, along with ESPN on ABC and other streaming options. The company said consumers will get access to over 47,000 live events a year, along with on-demand replays, studio shows and original programming.
Additional details about the service, including a launch date, will be announced this summer.
Read Also:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45293256/disney-stock-resilient-in-uncertain-economy-as-raised-guidance-signals-confidence"> Disney Stock &#8216;Resilient&#8217; In Uncertain Economy As Raised Guidance Signals Confidence</a>
Why It's Important: The new streaming platform could be one of the final nails in the coffin for cable television, with live sports being one of the top reasons consumers have cable over streaming platforms.
Users will now be able to secure the ESPN and ESPN family of channels on their own outside of cable, a move that LightShed Partners analyst Rich Greenfield <a href="https://lightshedtmt.com/2025/05/14/espns-direct-to-consumer-trojan-horse/">said </a>could help Disney.
Greenfield predicted earlier this year that Disney would have two million ESPN DTC subscribers by the end of 2025.
"We feel even more confident after ESPN revealed their pricing and packaging yesterday," Greenfield said.
The analyst said the goal of launching the ESPN app direct-to-consumer could be to get existing ESPN subscribers to watch via the app instead of with a multichannel video programming distributor, or MVPD.
"If ESPN can drive MVPD and vMVPD subscribers to use the ESPN app instead of watching on Comcast, DirecTV, or YouTube TV, they will finally have a direct relationship with their viewers."
Greenfield said this would give Disney more options when it comes to targeting advertising and engaging with fans in other ways, such as through fantasy sports, merchandise and sports betting.
"We believe the best way to judge ESPN's DTC effort is not by DTC subscribers at year-end 2025 or 2026, but rather how many consumers are using the ESPN app in a year to watch ESPN and how much time spent occurs on the ESPN app."
The analyst said getting a "meaningful portion" to watch through the app would be a "big win for Disney."
"If not, the ESPN DTC launch will be a relatively minor event that helps offset the continued decline in multichannel video universe subscribers."
Greenfield highlighted in the recent note that Disney CEO Bob Iger previously called the launch of the ESPN DTC app the biggest development for the sports company since landing Monday Night Football rights in 2005.
DIS Price Action: Disney stock was up 1.35% to $112.94 at market close on Wednesday versus a 52-week trading range of $80.10 to $118.63. Disney stock is up 1.9% year-to-date in 2025 and up 7.25% over the past year.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/education/25/05/45262536/disney-expands-to-abu-dhabi-with-new-theme-park-heres-how-the-stock-performs-after-park-openings">Disney Expands To Abu Dhabi With New Theme Park: Here&#8217;s How The Stock Performs After Park Openings</a></li>
</ul>

Analyst Color

Entertainment

Sports

Media

ESPN To Launch 'Ultimate Sports Destination' Streaming App In Fall: Why Analyst Says Disney Can 'Have A Direct Relationship With Their Viewers'

Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) has outperformed the market over the past 10 years by 6.03% on an annualized basis producing an average annual return of 16.71%. Currently, Fiserv has a market capitalization of $105.26 billion. 
Buying $1000 In FI: If an investor had bought $1000 of FI stock 10 years ago, it would be worth $4,661.43 today based on a price of $189.86 for FI at the time of writing.
<h3>Fiserv's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747260918_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Battalion Oil (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BATL#AMEX">BATL</a>) reported quarterly losses of $(1.00) per share. This is a 55.36 percent increase over losses of $(2.24) per share from the same period last year. The company reported $47.48 million in sales this quarter. This is a 4.80 percent decrease over sales of $49.87 million the same period last year.

BATL

UPDATE: Battalion Oil Q1 Adj. EPS $(1.00) Up From $(2.24) YoY, Sales $47.48M Down From $49.87M YoY

Foot Locker Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) shares are running after the market close on Wednesday following reports that Dick&#8217;s Sporting Goods Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) is nearing a deal to buy the <a href="https://www.benzinga.com/pressreleases/25/05/n45129350/foot-locker-inc-to-report-first-quarter-financial-results-on-thursday-may-29">footwear and apparel retailer</a>.
What To Know: Dick&#8217;s Sporting Goods is getting close to finalizing a deal to acquire Foot Locker for around $2.3 billion, according to a Wall Street Journal <a href="https://www.wsj.com/business/deals/dicks-sporting-goods-nears-deal-to-buy-foot-locker-7ecf9194">report</a>. 
The report indicates that a deal could be completed as soon as Thursday, citing people familiar with the matter. 
Discussions have reportedly involved a potential deal at $24 per share, representing a significant premium to Foot Locker&#8217;s closing price of $12.88 as of Wednesday&#8217;s close. 
Foot Locker shares have trended down since the start of the year. Shares sold off in February as markets began to move lower in anticipation of <a href="https://www.benzinga.com/trading-ideas/25/04/44672618/trump-tariffs-to-hurt-nike-under-armour-vf-are-ralph-lauren-foot-locker-safer-bets">tariffs</a> from the Trump administration. The company also reported mixed financial results in March as sales fell 5.8% year-over-year. Foot Locker guided for continued consumer and category promotional pressures and said it would continue to focus on inventory controls and expense management. 
The Wall Street Journal reported that the deal would be the biggest acquisition to date for Dick&#8217;s, the nation&#8217;s largest sports retail chain. The deal would also expand Dick&#8217;s operations outside the U.S. 
Dick&#8217;s Sporting Goods shares were down about 4.58% at $200, while Foot Locker shares were soaring 68.61% at $21.70 after-hours Wednesday at publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Foot Locker is due to report <a href="https://www.benzinga.com/calendars/earnings">first-quarter financial results</a> on May 29. Analysts have been anticipating a loss of four cents per share and revenue of $1.86 billion.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/insights/analyst-ratings/25/05/45357794/beyond-the-numbers-13-analysts-discuss-dicks-sporting-goods-stock">Beyond The Numbers: 13 Analysts Discuss Dick&#8217;s Sporting Goods Stock</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/Fotocute">C. Nass</a>/Shutterstock.

After-Hours Center

Foot Locker Stock Soars On Potential Dick's Sporting Goods Deal: Report

Fury Gold Mines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FURY#AMEX">FURY</a>) reported quarterly losses of $(0.02) per share. This is a 100 percent decrease over losses of $(0.01) per share from the same period last year.

FURY

Fury Gold Mines Q1 GAAP EPS $(0.02) Down From $(0.01) YoY

Spire Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.67) by 5.97 percent. This is a 18.87 percent decrease over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $23.90 million which beat the analyst consensus estimate of $22.70 million by 5.31 percent. This is a 6.96 percent decrease over sales of $25.69 million the same period last year.

Earnings Beats

SPIR

CORRECTION: Spire Global Q1 Adj. EPS $(0.63) Beats $(0.67) Estimate, Sales $23.90M Beat $22.70M Estimate

Across the recent three months, 14 analysts have shared their insights on OneStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OS#NASDAQ">OS</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">11</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for OneStream, revealing an average target of $29.5, a high estimate of $35.00, and a low estimate of $24.00. This current average has decreased by 11.81% from the previous average price target of $33.45. 
<img src="https://www.benzinga.com/files/images/story/2025/1747260078_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of OneStream by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Koji Ikeda</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$33.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Brett Huff</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Brian Peterson</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$29.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$32.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Outperform</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Nick Altmann</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$27.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$24.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Chris Quintero</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Terry Tillman</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$27.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Adam Hotchkiss</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$31.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Brett Huff</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$27.00</td>
<td>-</td>
</tr>
<tr>
<td>Brett Huff</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$27.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Quintero</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$34.00</td>
<td>$37.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to OneStream. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of OneStream compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for OneStream's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into OneStream's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on OneStream analyst ratings.</a>
<h2>Delving into OneStream's Background</h2>
OneStream Inc is an AI-enabled and extensible software platform that unifies core financial functions and broader operational data and processes within a single platform. The Digital Finance Cloud of the company provides a comprehensive, dynamic, and predictive view of the entire enterprise, providing corporate leaders the control, visibility, and agility required to proactively adjust business and day-to-day execution. Company platform unifies core financial and operational data and processes within a single platform, with solutions that maintain the integrity of corporate reporting standards for Finance while providing operationally insights for business users.
<h3>Key Indicators: OneStream's Financial Health</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, OneStream showcased positive performance, achieving a revenue growth rate of 23.59% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: OneStream's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -17.62%, the company may face hurdles in effective cost management.
Return on Equity (ROE): OneStream's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -6.01%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): OneStream's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.84%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.04, OneStream adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down OneStream: 14 Analysts Share Their Views

Ratings for Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $1.88, with a high estimate of $2.50 and a low estimate of $1.50. A decline of 37.33% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1747260071_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Biodesix by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bill Bonello</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1.50</td>
<td>$3.00</td>
</tr>
<tr>
<td>Thomas Flaten</td>
<td>Lake Street</td>
<td>Lowers</td>
<td>Buy</td>
<td>$2.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1.50</td>
<td>$2.50</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$2.50</td>
<td>$3.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Biodesix. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Biodesix compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Biodesix's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Biodesix's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BDSX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Biodesix analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Biodesix: A Closer Look</h2>
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
<h3>A Deep Dive into Biodesix's Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Biodesix showcased positive performance, achieving a revenue growth rate of 39.28% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Biodesix's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -40.39%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -33.86%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Biodesix's ROA excels beyond industry benchmarks, reaching -8.25%. This signifies efficient management of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.97, caution is advised due to increased financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDSX

Biodesix Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $279.57, along with a high estimate of $342.00 and a low estimate of $219.00. Highlighting a 0.76% decrease, the current average has fallen from the previous average price target of $281.71. 
<img src="https://www.benzinga.com/files/images/story/2025/1747260062_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Ralph Lauren among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$275.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$335.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$240.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$219.00</td>
<td>$282.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$286.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$342.00</td>
<td>$285.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ralph Lauren. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ralph Lauren compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Ralph Lauren's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Ralph Lauren's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ralph Lauren analyst ratings.</a>
<h2>Get to Know Ralph Lauren Better</h2>
Founded by designer Ralph Lauren in 1967 in New York City, Ralph Lauren Corp. designs, markets, and distributes lifestyle merchandise in North America, Europe, and Asia. Best known for its iconic polo shirts, its products also include other types of apparel, footwear, eyewear, jewelry, handbags, home goods, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, and Lauren Ralph Lauren. Distribution channels for Ralph Lauren include wholesale (department stores and specialty stores), retail (company-owned retail stores and e-commerce), and licensing.
<h3>A Deep Dive into Ralph Lauren's Financials</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Ralph Lauren's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 10.83%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Ralph Lauren's net margin excels beyond industry benchmarks, reaching 13.87%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Ralph Lauren's ROE excels beyond industry benchmarks, reaching 11.94%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.29%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.06.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Ralph Lauren: 7 Analysts Share Their Views

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $143.68, along with a high estimate of $171.44 and a low estimate of $132.00. Experiencing a 2.01% decline, the current average is now lower than the previous average price target of $146.63. 
<img src="https://www.benzinga.com/files/images/story/2025/1747260047_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive BioNTech. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$134.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$140.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$132.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$145.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$145.00</td>
<td>-</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$139.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>John Newman</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$171.44</td>
<td>$171.44</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$143.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to BioNTech. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of BioNTech compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for BioNTech's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into BioNTech's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BNTX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on BioNTech analyst ratings.</a>
<h2>All You Need to Know About BioNTech</h2>
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
<h3>Key Indicators: BioNTech's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: BioNTech's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -2.56%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: BioNTech's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -227.46%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): BioNTech's ROE stands out, surpassing industry averages. With an impressive ROE of -2.17%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): BioNTech's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -1.9%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.02.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BNTX

Where BioNTech Stands With Analysts

KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for KKR, presenting an average target of $135.93, a high estimate of $194.00, and a low estimate of $114.00. Observing a downward trend, the current average is 11.45% lower than the prior average price target of $153.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1747260037_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of KKR by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$141.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$136.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$131.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Vikram Gandhi</td>
<td>HSBC</td>
<td>Lowers</td>
<td>Buy</td>
<td>$119.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$114.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$129.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$126.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Chris Allen</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$132.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$150.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$194.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$141.00</td>
<td>$150.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to KKR. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of KKR compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for KKR's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into KKR's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/KKR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on KKR analyst ratings.</a>
<h2>Unveiling the Story Behind KKR</h2>
KKR is one of the world's largest alternative asset managers, with $624.4 billion in total managed assets, including $505.7 billion in fee-earning AUM, at the end of September 2024. The company has two core segments: asset management (which includes private markets-private equity, credit, infrastructure, energy, and real estate-and public markets-primarily credit and hedge/investment fund platforms) and insurance (following the firm's initial investment in, and then ultimate purchase of, Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance).
<h3>Unraveling the Financial Story of KKR</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Negative Revenue Trend: Examining KKR's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -68.18% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: KKR's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -6.53%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -0.82%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): KKR's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.05%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.04, caution is advised due to increased financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying KKR: Insights From 14 Analyst Reviews

Ratings for Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Corteva and provided 12-month price targets. The average target is $73.2, accompanied by a high estimate of $79.00 and a low estimate of $69.00. This current average has increased by 4.08% from the previous average price target of $70.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1747260029_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Corteva. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin Theurer</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Richard Garchitorena</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$79.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Kristen Owen</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$71.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$78.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$72.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$76.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Bradley Thomas</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$71.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Bill Selesky</td>
<td>Argus Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$69.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$71.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Corteva. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Corteva compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Corteva's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Corteva's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CTVA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Corteva analyst ratings.</a>
<h2>Discovering Corteva: A Closer Look</h2>
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva operates globally, but around half of revenue comes from North America.
<h3>A Deep Dive into Corteva's Financials</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Challenges: Corteva's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -1.67%. This indicates a decrease in top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Corteva's net margin is impressive, surpassing industry averages. With a net margin of 14.76%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.71%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Corteva's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.57% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Corteva's debt-to-equity ratio is below the industry average at 0.17, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTVA

Expert Outlook: Corteva Through The Eyes Of 10 Analysts

Press Releases

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

Legal

Septerna, Inc. Investors: Company Investigated by the Portnoy Law Firm

Kirby McInerney LLP Announces Investigation Against Septerna, Inc. (SEPN) on Behalf of Investors

SEPTERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Septerna, Inc. on Behalf of Septerna Stockholders and Encourages Investors to Contact the Firm

Septerna to Present at TD Cowen 45th Annual Health Care Conference

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN

SEPN Investors Have Opportunity to Join Septerna, Inc. Fraud Investigation with the Schall Law Firm

Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

SEPN

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Alumis

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Bioage Labs

Journey Medical Corporation - Common Stock

Journey Medical

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

Maze Therapeutics

MBX Biosciences

NeOnc Technologies Holdings, Inc. - Common Stock

NeOnc Technologies

Omeros

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

SIGA Technologies

SNDL

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Third Harmonic Bio

Tilray Brands

Tvardi Therapeutics

Zevra Therapeutics

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology

Wells Fargo

Cantor Fitzgerald

JP Morgan

WIIM

Septerna shares are trading higher after the company announced an exclusive global collaboration and license agreement with Novo Nordisk to develop oral small molecule medicines for obesity, type 2 diabetes, and other cardiometabolic diseases.

Comments

Septerna

Intérêt court

Septerna (NASDAQ:SEPN) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL